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Abstract
Background: The use of nicotine replacement therapy (NRT) can almost double the chances of success for smokers
to quit. Nevertheless, there is still a considerable number of cessation attempts that are made without any treatment.
This novel oral formulation, (lozenge containing nicotine bitartrate dihydrate) has been developed to enlarge the offer
for efficient smoking cessation drug therapies, assuming that increasing treatment options will bring more smokers to
find the support they personally need to stop smoking.
Methods: Three pharmacokinetic (PK), one safety and two efficacy studies were carried out with Nicotinell lozenges.
PK trials were: (1) a single-dose, three-way crossover study comparing 1 and 2 mg lozenges with 2 mg nicotine gum; (2)
a multiple-dose, two-way crossover study comparing 1 mg lozenge with 2 mg gum; (3) a multiple-dose, three-way
crossover study comparing 1 and 2 mg lozenges with 4 mg gum. Safety trial: (4) a single dose study to assess the safety
of swallowing up to 12 lozenges containing 1 mg nicotine. Efficacy trials: two efficacy studies in (5) France and (6) the
USA, including more than 900 smokers followed-up for up to one year, conducted with the 1 mg lozenge.
Results: The results of the individual PK trials showed that the 1 mg Nicotinell lozenge is bioequivalent to 2 mg
polacrilex gum, as demonstrated by similar blood PK parameters (tmax, Cmax, AUC). The 2 mg lozenge was found to
deliver quantities of nicotine that were intermediate between those delivered by 2 and 4 mg polacrilex gum.
The short-term efficacy of the 1 mg lozenge in comparison with placebo was also demonstrated with significantly more
subjects continuously abstinent from smoking with active lozenges on week 6 in two different populations: moderate to
heavy smokers (FTND between 4 and 7) OR = 1.72 [95% CI: 1.05–2.80]; heavy to very heavy smokers (FTND 6 and
over) OR = 2.87 [95% CI: 1.18–6.97].
Nicotinell lozenges were found to be safe with mainly mild and reversible adverse events. The safety of the 1 mg lozenge
formulation, even when misused was also demonstrated.
Conclusion: The data presented in this review demonstrate high nicotine bioavailability, excellent safety profile and
proven short-term efficacy of Nicotinell lozenges. At nominal equivalent doses 1 and 2 mg Nicotinell lozenges were
shown to deliver larger amounts of bioavailable nicotine compared to the nicotine polacrilex gum. According to the data
developed here, the systemic exposure to nicotine could be ranked: 4 mg polacrilex gum > 2 mg Nicotinell lozenge > 1
mg Nicotinell lozenge = 2 mg polacrilex gum.
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Adverse events observed during the clinical trials were mild or moderate in severity, transient and completely reversible. 
With respect to efficacy in smoking cessation, significantly higher continuous abstinence rates were achieved with lozenge 
compared to placebo. In conclusion, Nicotinell lozenges offer a valuable addition to the therapeutic armamentarium 
available for smoking cessation.
Background
Smoking is still the largest preventable cause of death and
disease in the developed world and increases the risk for
cancer, cardiovascular and lung diseases, among others
[1-3]. Accordingly, smoking cessation provides immedi-
ate and lasting benefits to public health [4-6]. However,
relatively few smokers succeed in quitting each year [7].
Nicotine replacement therapy (NRT) helps smokers quit
by providing nicotine at levels usually lower than those
obtained through smoking and without the toxins con-
tained in tobacco smoke. NRT can reduce the craving for
nicotine and the nicotine withdrawal symptoms which
might otherwise jeopardize the smoking cessation efforts
[8]. NRT has a well established success record [9] and its
use is endorsed by health authorities [4,10-12].
Several forms of NRT are available for smokers to choose
from, according to their specific needs and preferences
[8,13]. Beside nicotine patches, which deliver nicotine
slowly and continuously through the skin, a number of
acute dosage forms have been developed, which allow
smokers to self-administer the amount of nicotine
needed, in order to achieve a consistent concentration of
nicotine in the blood, and to ward off acute urges to
smoke ('rescue medication' use) [14]. The first available
acute dosage form was nicotine-polacrilex chewing-gum,
which was launched in the 1980s. More recent additions
are the vapor inhaler, sublingual tablet, lozenge (all for
oral nicotine administration), and nasal spray (uptake via
the nasal mucosa) [15].
The efficacy and safety of nicotine lozenges containing 2
or 4 mg of nicotine coupled to a polacrilex resin, from
which it is released upon dissolution of the lozenge in the
mouth, have been described and compared with nicotine-
polacrilex gum also using a polacrilex resin [16]. The effi-
cacy of the Nicotinell lozenges studied in this review has
previously been described [17,18]. The versatility of loz-
enges has also been demonstrated in the treatment of
smokers who had previously failed to quit on other NRT
products, and of both very heavy and moderate/light
smokers [19-21]. Indeed, when compared to the gum, loz-
enges are characterized by a number of advantages, such
as fewer potential oral health limitations (e.g. dental
works or temporomandibular joint pain), better social
acceptance (e.g. at workplaces), and greater ease of use as
they do not require chewing. As opposed to patches, loz-
enges provide all the advantages of acute dosage forms
described above [22], including the possibility of self-
adaptation of the dose and some degree of behavioral
activity and sensory stimulation, which might be crucial
for smokers trying to quit.
Despite considerable literature, there are few published
studies directly comparing different NRT products [9]. In
addition, pharmacokinetic (PK) data on nicotine lozenges
in the literature remain scarce [23]. The present review
provides the first comprehensive description of the PK
profiles of 1 and 2 mg Nicotinell lozenges in comparison
with 2 and 4 mg nicotine gum. In addition, the efficacy
and safety of the 1 mg Nicotinell lozenge in smoking ces-
sation are documented.
Methods
General
All presented studies were carried out in compliance with
the Helsinki Declaration and its amendments and Good
Clinical Practices. All protocols were accepted by local
ethics committees (Table 1). All subjects provided written
informed consent before enrolment in the studies.
Participants to the studies were adult, healthy smokers
usually smoking at least 20 cigarettes per day in the PK tri-
als, or at least 10 cigarettes per day in the safety trial. Dur-
Table 1: Ethic committee approvals
Study Ethical Committee
- single-dose, comparing 1 and 2 mg lozenges with 2 mg gum
- multiple-dose, comparing 1 mg lozenge with 2 mg gum
CCPPRB de Franche-Comté, France
- multiple-dose, comparing 1 and 2 mg lozenges with 4 mg gum CCPPRB of the Hôtel-Dieu Hospital (Lyon – France)
- safety assessment of 1 mg lozenge after swallowing CREC Regipharm (Brussels – Belgium)
- French efficacy trial CCPPRB of the Pitié-Salpêtrière Hospital (Paris – France)
- US efficacy trial IRB at Research Testing Laboratories, Inc. (Great Neck, NY, USA)BMC Clinical Pharmacology 2007, 7:11 http://www.biomedcentral.com/1472-6904/7/11
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ing the PK and safety trials, participants were maintained
under highly controlled conditions, including standard-
ized food and fluid intake, restricted physical activity, and
cigarette abstinence. Non-smoking compliance was con-
trolled by measurement of carbon monoxide (CO) in
expired air. Blood samples were collected at planned time-
points. Concentrations of nicotine and cotinine in plasma
or urine were determined by validated GC-MS methods
with limits of quantification at respectively 1 ng/ml and
10 ng/ml for nicotine and cotinine (LC-MS/MS for the
multiple-dose study comparing 1 and 2 mg lozenges with
4 mg gum). Residual nicotine content in the chewed gum
(or sucked lozenge) after use was determined by HPLC.
Single-dose pilot study comparing 1 and 2 mg lozenges 
with 2 mg gum
This was a single-center, open-label, single-dose, rand-
omized, three-way, crossover pilot study in nine male vol-
unteers to assess the PK parameters of 1 mg Nicotinell
lozenges (containing 3.07 mg nicotine bitartrate dihy-
drate equivalent to 1 mg nicotine base), 2 mg Nicotinell
lozenges (containing 6.134 mg nicotine bitartrate dihy-
drate equivalent to 2 mg nicotine base), and 2 mg nicotine
gum (Nicorette® gum; Pharmacia A.B.; containing 10 mg
nicotine carboxylate cation resin equivalent to 2 mg nico-
tine base). The same brand of comparator gum was used
throughout the ensuing clinical development. Subjects
were randomized to one of the three groups and received
one piece of trial medication during each of the three 32-
hour observation periods, which always started with a 24-
hour non-smoking phase, and were separated by 7-day
washouts. Lozenges were sucked and gum chewed for 30
min according to a controlled schedule, and remainders
were collected to measure drug delivery. In this pilot
study, lozenges were not completely dissolved at the end
of 30 min, therefore the sucking pattern was modified for
subsequent studies. Blood was drawn before dosing and
at 15, 30, 45 min, 1, 1.25, 1.5, 2, 3, 4, 6, and 8 h after dos-
ing. Urine was collected during the 24 h run-in preceding
administration and between 0–4 h and 4–8 h after dosing.
Main criteria for comparison between different drugs were
AUC0–∞ and Cmax, which were corrected for 100% drug
delivery from lozenge. Ln-transformed values were sub-
mitted to 4-factor ANOVA (sequence, subject, period,
treatment).
Multiple-dose study comparing 1 mg lozenge with 2 mg 
gum
This was a single-center, open-label, multiple-dose, rand-
omized, two-way, crossover PK study in 24 male volun-
teers that compared 1 mg Nicotinell lozenges with 2 mg
nicotine polacrilex gum. Two 2-day observation periods
were separated by a 7-day washout and each period
started with a 22-hour run-in phase without smoking, fol-
lowed by a 12-hour dosing phase and a 23-hour sampling
phase. Twelve doses of nicotine were administered, i.e.
one per hour from t = 0 to t = 11. Lozenges were sucked
until complete dissolution, and the time needed to
achieve this (usually about 30 min) was reported. Gum
was chewed for 30 min according to a schedule monitored
by a computer-controlled beeper, and residues were col-
lected and frozen for HPLC analysis. Blood was drawn
pre-dose, 15, 30 and 45 min after the first dose. In addi-
tion, blood was drawn before each new dose (at 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, and 11 h) and after the last dose at 11.25,
11.5, 11.75, 12, 12.25, 12.5, 13, 13.5, 14, 15, 17, 19, 21,
and 23 h (all times after first dose).
Main criteria for comparison of nicotine PK at steady state
were Cmax, tmax and AUC11–12 (AUC during one dosing
interval). Secondary criteria were first dose data (Cmax,
tmax, AUC0–1), Cmin before each dose and t1/2 after the last
dose. In addition, urinary and saliva pH variations were
assessed and safety was controlled through assessment of
cardiovascular parameters (blood pressure (BP), heart rate
(HR), and ECG), standard laboratory tests and incidence
of adverse events (AEs). Cmax and AUC11–12, ln-trans-
formed values were submitted to 4-factor ANOVA
(sequence, subject, period, treatment). A 90% confidence
interval (CI) was constructed for the ratio (e.g. for loz-
enge/gum) of Cmax and AUC11–12 respectively. The pri-
mary criterion for relative bioequivalence was that the
90% confidence limits fall within the interval [0.80–
1.25], i.e. the standard bioequivalence acceptance range
(BAR). When appropriate, the enlarged BAR [0.7–1.43]
was applied.
Multiple-dose study comparing 1 and 2 mg lozenges with 4 
mg gum
This was a single-center, open-label, multiple-dose, rand-
omized, three-way, crossover PK study in 31 male volun-
teers. Its primary objectives were: (1) to confirm the dose-
concentration proportionality between Nicotinell 1 and 2
mg lozenges and (2) to compare nicotine systemic expo-
sure by Nicotinell 2 mg lozenge with that of Nicorette 4
mg gum. Secondary objectives were the completion of the
PK profile of the 2 mg Nicotinell lozenge and the compar-
ison of clinical safety of the three nicotine formulations.
There were three treatment periods of 12 h (one for each
product), separated by 7-day washout periods. Smoking
was prohibited during the 24 h preceding treatment and
until leaving the study center. During each treatment
period, a total of twelve doses of nicotine were adminis-
tered at a rate of 1 dose per hour. Lozenges were sucked
until complete dissolution and gum were chewed for 30
min at 60 chews/min (timed using a calibrated metro-
nome) while the subjects remained in a seated position.
Blood samples for determination of plasma nicotine and
cotinine concentrations were drawn pre-dose and at 7 and
9 h. After intake of the last dose (11 h), blood was drawnBMC Clinical Pharmacology 2007, 7:11 http://www.biomedcentral.com/1472-6904/7/11
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at 11.25, 11.5, 11.75, 12.5, 13, 14, 15, 17, 19, 21, and 23
h. Tolerability was assessed by spontaneous reporting of
AEs.
Primary PK parameters for evaluation were steady state
data after the last dose (AUC11–12, Cmax and tmax). For the
comparison between 1 and 2 mg lozenges (dose propor-
tionality) and between 2 mg lozenge and 4 mg gum, ln-
transformed values for Cmax and AUC1112 were submitted
to 4-factor ANOVA (sequence, subject, period, treatment).
Relative bioequivalence was determined by construction
of 90% CIs and application of the standard BAR [0.80–
1.25] and enlarged BAR [0.7–1.43] for the ratios of Cmax
and AUC11–12, and by Friedman ANOVA for tmax. In addi-
tion, complete safety and tolerability data were collected,
including physical examination and vital signs, cardiovas-
cular parameters, standard laboratory tests and incidence
of AEs.
Safety of 1 mg lozenge after swallowing
This was a single-center, open-label, escalating-dose,
sequential group safety study with 24 volunteers of both
sexes. The participants were divided into three groups of
eight: subjects in group A swallowed three lozenges, in
group B six lozenges, and in group C 12 lozenges. For
every group, subjects were included in two steps: first, two
volunteers were assessed, and if the administered dose
was well tolerated the other six volunteers were included.
Each dose level was followed by a 2-day observation
period, including a 12 h period after dosing during which
smoking was prohibited. Lozenges were swallowed as a
single dose with 250 ml of water. Safety was assessed by
examination of the plasma nicotine levels, subjects' clini-
cal status, standard laboratory testing, gastric motility test
(only the first two subjects of each group) and AEs report-
ing. Blood for determination of plasma nicotine levels
was drawn pre-dose and 10, 20, 30, 40, 50 min, 1, 1.5, 2,
2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 13, 16 and 48 h post-
dose.
Criteria for safety evaluation were as follows: (1) Cmax and
tmax after each dose, as well as AUC10 min-12 h for nicotine
PK; (2) BP, HR, ECG, and physical examination for clini-
cal status; (3) hematology, biochemistry (including
hepatic parameters, serology and urinalysis), carboxyhe-
moglobin, carcinoembryonic antigen, and urinary coti-
nine and catecholamine levels for laboratory testing; and
(4) gastric emptying and antral motor activity for gastric
motility. Nicotine PK parameters were analyzed by sum-
mary statistics of all nicotine concentrations, AUC, tmax,
Cmax, and comparison of PK values by one-way ANOVA.
BP and HR were analyzed by an ANOVA GLM model for
systolic and diastolic values, as well as for the difference
(systolic – diastolic); factors for ANOVA were subject,
period and treatment. All other parameters were analyzed
within each treatment group by Wilcoxon paired test (pre-
vs. post-dosing). Post-entry differences of each treatment
group were compared by one-way ANOVA or Kruskal-
Wallis test, as appropriate. For all parameters, McNemar
test was used to detect volunteers who changed their sta-
tus from entry to post-dosing in terms of normal range
limits.
Efficacy trials with 1 mg lozenge
Two large phase 3 studies were performed to assess the
efficacy of 1 mg Nicotinell lozenge in smoking cessation,
one in France (37 centers; AFSSAPS trial registration
number: 980324) and one in the USA (3 centers; registra-
tion number 905.1295). The 2 trials had a double-blind,
placebo-controlled, randomized, parallel groups design.
The patients, respectively for the French and the American
trials, were distributed as follows: (1) randomized and
received at least one treatment: 436 and 460 patients, (2)
received active lozenge: 214 and 230 patients, (3) received
placebo lozenges: 222 and 230 subjects. Eligible subjects
were healthy smokers of both sexes and aged ≥ 18 years,
motivated to quit. To have a global view on the lozenge
efficacy over a wide range of dependence levels, patients
had either a medium to high dependence of smoking in
the French study (Fagerström Test for Nicotine Depend-
ence (FTND) [24] score of 4–7 and smoking 10–30 ciga-
rettes/day), or a high to very high dependence in the US
study (FTND score ≥ 6 and smoking 20–40 cigarettes/
day). Subjects were advised to suck between 8 and 25 loz-
enges each day (dosage self-adjusted by subjects) for six
weeks, followed by complete weaning over the next six
weeks with a suggested decrease of one lozenge per day
relative to the dose at week 6. Subjects attended the study
site at screening (baseline), biweekly or weekly up to week
6, and then at week 12, and 26. After week 6, only absti-
nent subjects were continuously followed-up. At visits,
smoking status (exhaled-breath CO), BP, HR, weight, and
AEs were recorded. From weeks 0–6 (France) or 0–12
(USA), subjects recorded daily in a diary the number of
lozenges used and of cigarettes smoked (if any), plus any
withdrawal symptoms experienced. During the study no
formal behavioral counseling was offered to patients. The
primary efficacy outcome measure was the proportion of
patients continuously and completely abstinent (no ciga-
rettes and CO <10 ppm) during the four weeks preceding
week 6 and the number of subjects to include was calcu-
lated according to this objective. Secondary efficacy out-
comes were the point prevalence abstinence rates at the
visits on week 12 and on week 26, the evolution of with-
drawal symptom scores, and partial abstinence rates (par-
tial abstinence defined as smoking of ≤ 1 cigarette per day
and ≤ 7 cigarettes per week, and CO <10 ppm) on week 6,
12 and 26. Safety of treatment (AEs, BP, HR, weight) and
levels of urine nicotine metabolites (French study only)
were further outcome measures. Efficacy was analyzedBMC Clinical Pharmacology 2007, 7:11 http://www.biomedcentral.com/1472-6904/7/11
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using Cochran-Mantel-Haenszel statistic, stratified by
study center. Comparison between treatments was made
using the Cochran-Mantel-Haenszel chi-square test, after
adjusting for pooled centers. The experimental details and
results of the French trial have previously been described
[17,18].
Results
Single dose pilot study: PK comparison of 1 and 2 mg 
lozenges with 2 mg gum
Key PK results are summarized in Table 2. The sucking
pattern in this trial did not result in full dissolution of the
lozenges and only approximately 67% of their nicotine
content was released. Thus, a correction was applied to
calculate Cmax and AUC0–∞ for a fully dissolved lozenge.
This was deemed appropriate because lozenges are
designed to be fully sucked out by users. The adjusted val-
ues for Cmax and AUC0–∞ of 1 mg lozenge and 2 mg gum
were similar and thus indicated comparable nicotine
delivery from these two formulations. In addition, com-
parison of PK parameters of 1 and 2 mg lozenges demon-
strated dose-concentration proportionality between these
doses, which was verified in an ensuing multiple-dose
study (see below).
During metabolization, nicotine is converted into several
metabolites including cotinine, which are finally excreted
in urine. Further support for comparable PK properties of
1 mg lozenge and 2 mg gum came from mean plasma
cotinine kinetics, including Cmax (19.9 → adjusted 29.7
ng/ml with lozenge vs. 30.2 ng/ml with gum), AUC0-t
(102 → 152 h.ng/ml vs. 153 h.ng/ml), tmax (5.2 vs. 5.3 h),
and t1/2 (9.4 vs. 11.4 h). Similarly, urinary cotinine values
were comparable between 1 mg lozenge and 2 mg gum,
and dose-concentration relationship was apparent for uri-
nary cotinine excretion after dosing with 1 mg vs. 2 mg
lozenges (data not shown). Among the 18 AEs observed,
only 2 were considered to be related to study drug (throat
irritation with 2 mg lozenge and gum), but none was seri-
ous. No other clinically relevant abnormalities were noted
with any of the products.
Bioequivalence of 1 mg lozenge and 2 mg gum at steady 
state
As the pilot study suggested bioequivalence of 1 mg loz-
enges and 2 mg gum, this trial was designed to confirm
this bioequivalence between these two formulations,
focusing on PK characteristics after multiple doses and at
steady state. Median duration for complete dissolution of
lozenges over the entire study period was 29.25 min
(range 27–31 min). The mean amount of nicotine
extracted from the gum increased from 1.0 mg at dose 1 to
1.13 mg at dose 12 (+13%). Therefore, an adjustment was
applied to the amount of nicotine actually delivered by
gum at different time-points in order to ensure consistent
statistical analysis of PK parameters. Both NRT products
led to an increase in saliva pH after dosing, the lozenge
having a significantly higher buffering power than the
gum (data not shown), which is known to favor a non-
ionized state of nicotine and its absorption [25,26]. As
expected, median tmax (0.76 vs. 0.75 h), mean Cmax (4.2 ±
1.8 vs. 5.0 ± 1.6 ng/ml) and AUC0–1 (2.9 ± 1.4 vs. 3.5 ± 1.3
h.ng/ml) were similar for lozenge and gum after the first
dose (0–1 h).
Plotting of plasma nicotine concentrations over time after
repeated administration of Nicotinell 1 mg lozenges and
2 mg polacrilex gum revealed that the plateau of concen-
tration was reached after intake of six doses (Figure 1).
The blood draws after the last dose allowed to determine
PK characteristics at steady state. The observed kinetics
Table 2: PK parameters of nicotine in plasma after intake of a single dose of lozenge or gum (mean ± SD; n = 9)
Formulation\PK parameter Nicotinell® 
lozenge
Nicorette® 
gum
1 mg 2 mg 2 mg
Amount of nicotine released after 30 min (mg) 
[% of minimal content]
0.67 ± 0.14 
[67%]
1.39 ± 0.28 
[67%]
0.81 ± 0.25 
[42%]
observed Cmax (ng/ml) 
[adjusted]†‡
2.3 ± 0.8 
[3.5 ± 1.1]†
4.8 ± 1.4
[7.0 ± 1.7]
2.9 ± 1.2
tmax (h) 
[median (range)]
1.1 ± 0.7 
[0.8 (0.8–3.0)]
0.8 ± 0.2 
[0.8 (0.6–1.1)]
0.8 ± 0.1
[0.8 (0.5–1.0)]
t1/2 (h) 2.7 ± 0.7 2.8 ± 0.7 2.5 ± 1.0
AUC0-t (h·ng/ml) 8.3 ± 2.5 15.8 ± 4.1 10.6 ± 4.4
observed AUC0–∞(h·ng/ml) 
[adjusted]†‡
10.7 ± 3.1 
[16.5 ± 4.6]
20.0 ± 5.9 
[30.1 ± 9.7]
13.8 ± 5.6
†: Since in this trial nicotine lozenges were not completely dissolved after 30 min of sucking, an adjustment was made for nicotine delivery by a full 
1 mg dose.
‡: Adjustment for nicotine delivery by a full 2 mg dose.BMC Clinical Pharmacology 2007, 7:11 http://www.biomedcentral.com/1472-6904/7/11
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suggested that intake of lozenges or gum under these con-
ditions lead to "peak-trough" kinetics of nicotine similar
to those observed during day-time in dependent smokers
having cigarettes, but much reduced in intensity. Indeed,
the highest concentration (approximately 11 ng/ml)
obtained with the tested formulations corresponds to the
lower end of the range of blood nicotine levels (10–50 ng/
ml) observed in smokers in the afternoon (i.e. at steady
state) [14].
The determined values for Cmax, tmax  and AUC11–12
showed that nicotine delivery characteristics of 1 mg
Nicotinell lozenge and 2 mg polacrilex gum at steady state
were comparable (Table 3). When bioequivalence was sta-
tistically assessed, the 90% CIs for Cmax and AUC11–12
remained within the standard BAR [0.80–1.25], indicat-
ing bioequivalence of the 1 mg lozenge and the 2 mg gum
under the studied conditions. When unadjusted values for
gum were considered, the 90% CIs for Cmax and AUC11–12
of lozenge (0.76–0.93 and 0.75–0.91, respectively) still
fell within the enlarged BAR [0.7–1.43], which may be
considered acceptable for oral nicotine, due to its broad
therapeutic range and self-titration behavior of users [27-
29].
With respect to safety, 12 volunteers had a total of 40 AEs,
which were all mild to moderate, with complete recovery.
Six AEs (2 for lozenge and 4 for gum) were considered as
drug-related: headache, salivation, hiccups, flatulence and
throat irritation. No other clinically relevant abnormali-
ties were observed, neither for cardiovascular parameters,
nor for laboratory testing.
Nicotine plasma concentration after repeated intake (24 subjects) Figure 1
Nicotine plasma concentration after repeated intake (24 subjects). Nicotine plasma concentrations were determined 
in this multiple-dose bioequivalence trial with 24 volunteers from blood samples drawn before administration of each single 
dose (unconnected data points). Consecutive blood samples (connected data points) were drawn after administration of dose 
1 (t = 0) and dose 12 (t = 11 h). The insert shows a blood nicotine peak after dosing at steady state obtained with blood draws 
after dose 12 (11–12 h).
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Dose proportionality between 1 and 2 mg lozenges and 
comparison with 4 mg gum at steady state
This study was performed to confirm the dose-concentra-
tion proportionality between 1 and 2 mg Nicotinell loz-
enges, and to compare the nicotine PK profile of lozenges
with that of 4 mg nicotine gum. Overall trial design was
comparable to the previous multiple-dose study, with
intake of 12 doses of nicotine by 31 volunteers (1 dose per
hour, 30 min of sucking or standardized chewing) and
assessment of plasma nicotine PK parameters at steady
state (successive blood draws after dose 12). Thirteen out
of 31 (42%) of all trial participants had significant base-
line plasma nicotine levels on two or three periods, but no
differences were observed between the three treatment
groups. Thus, these baseline levels were not taken into
account, as they did not influence the comparison
between groups. The plateau concentration for plasma
nicotine was reached before the 12th dose. With respect to
dose-concentration proportionality between the 1 and 2
mg lozenge, an adjustment for the same dose (2 mg) was
applied, and Cmax and AUC11–12 were determined (Table
4). As expected, the 90% CIs of the ratio of Cmax and
AUC11–12 fell within the standard BAR [0.80–1.25], thus
demonstrating a linear dose-concentration relationship
between the two strengths of nicotine lozenge (Figure 2).
In addition, tmax did not to differ significantly (Friedman
ANOVA).
As bioequivalence between 1 mg lozenges and 2 mg gum
had been shown (see above) and as 1 and 2 mg lozenges
showed dose proportionality, one of the aims of this study
was to compare 2 mg lozenge with 4 mg gum. With 2 mg
lozenges, Cmax and AUC11–12 were approximately 26%
lower than with 4 mg gum. No bioequivalence was
observed (Table 5, Figure 3).
Analysis of safety and tolerability was considered of par-
ticular value in this trial, as participants were treated with
a wide range of nicotine doses under consistent condi-
tions. Overall, no significant variations were reported in
physical examination, vital signs, cardiovascular parame-
ters or clinical laboratory tests. There were no serious or
unexpected AEs. One subject was withdrawn due to vom-
iting when taking the 2 mg lozenges. The relationship was
considered probable. Sixteen subjects reported a total of
29 AEs during the entire trial, which were all mild to mod-
Table 3: PK parameters of nicotine in plasma at steady state after 12 hourly doses† of 1 mg lozenge or 2 mg gum (mean ± SD; n = 24)
Formulation\PK parameter Nicotinell® lozenge Nicorette® gum 90% CI (lozenge/gum)#
1 mg 2 mg‡
Cmax (ng/ml) 10.6 ± 2.9 11.4 ± 3.8 0.86–1.04
Cmin (ng/ml) 8.1 ± 2.4 9.3 ± 3.4 ND
tmax (h) [range] 0.54 ± 0.21 [0.00–0.77] 0.47 ± 0.19 [0.20–0.95] ND
t1/2 (h) 3.6 ± 1.2 3.2 ± 0.9 ND
AUC11–12 (h·ng/ml) 9.2 ± 2.6 10.2 ± 3.4 0.84–1.01
Initial nicotine concentrations in plasma were 1.1 ng/ml (range: 0.0–6.5) with lozenge and 0.9 ng/ml (0.0–5.1) with gum, reflecting volunteers' heavy 
smoking habits (≥ 20 cigarettes per day). Correction for initial nicotine concentrations did not modify the results and thus was not retained. ND: 
not determined.
†: PK parameters were determined from blood samples drawn after dose 12 (t = 11 h) until t = 23 h.
‡: a dose adjustment of the raw data was done for a last standard dose of 1 mg nicotine delivery from the gum.
#: Standard 90% CI for the expected mean ratio was derived from ANOVA for continuous parameters and compared to standard BAR [0.80–1.25].
Table 4: Steady state† plasma nicotine PK parameters after intake of 1 or 2 mg lozenges to determine dose-concentration 
proportionality (mean ± SD; n = 31)
Formulation\PK 
parameter
Nicotinell® lozenge 1 mg Nicotinell® lozenge 90% CI (2 mg/1 mg)#
observed adj. to 2 mg‡ 2 mg
Cmax (ng/ml) 11.0 ± 4.9 22.0 ± 9.8 22.5 ± 7.0 0.97–1.19 (F = 1.07)
tmax (h) Median [range] 0.5 [0.25–1.00] - 0.5 [0.25–1.02] NS (Friedman ANOVA)
AUC11–12 (h·ng/ml) 9.7 ± 3.9 19.3 ± 7.8 20.2 ± 6.8 0.98–1.20 (F = 1.08)
NS: not significant.
†: PK parameters were determined from blood samples drawn after dose 12 (t = 11 h) until t = 23 h.
‡: Experimental values (plasma nicotine concentrations) observed with 1 mg lozenge were adjusted to a hypothetical 2 mg dose before calculation 
of PK parameters.
#: Standard 90% CI for the expected mean ratio was derived from ANOVA for continuous parameters and compared to standard BAR [0.80–1.25]. 
F: relative bioavailability ratio.BMC Clinical Pharmacology 2007, 7:11 http://www.biomedcentral.com/1472-6904/7/11
Page 8 of 15
(page number not for citation purposes)
erate. The most frequent AEs assessed as at least possibly
related to treatments were: hiccup (reported by 10 sub-
jects, nine of which under the gum), throat irritation (two
times with 2 mg lozenges and three times with gum), and
nausea (ditto). Globally, more AEs were reported with the
4 mg gum than with the 1 or 2 mg lozenges, suggesting
overall good tolerability of the latter formulation.
Safety in case of misuse of 1 mg lozenges
All clinical assessments performed in the PK trials, as well
as reported AEs, suggested a favorable safety profile for
Nicotinell® lozenges. However, in these trials one lozenge
at a time was administered and subjects were sucking
them slowly without concomitantly smoking. Yet, nico-
tine from oral formulations is not only taken up via the
oral mucosa, but is also partially absorbed from the gas-
trointestinal tract [26]. To assess the safety in case of swal-
lowing large quantities of 1 mg lozenges, an escalating-
dose safety open study was performed: three groups (A, B,
C), each including eight male or female subjects who were
at least moderate smokers (≥ 10 cigarettes/day) received
either 3, 6, or 12 Nicotinell 1 mg lozenges, to be swal-
lowed at once with water. Smoking abstinence prior to
dosing was not asked for and all of the volunteers (except
one) had measurable levels of nicotine in plasma before
lozenge intake. Blood was drawn until 48 h post-dose and
plasma nicotine PK parameters were determined (Table
6). The highest mean concentration observed (20.5 ± 8.8
ng/ml) under these experimental conditions of misuse
still fell largely within the range of plasma nicotine con-
centrations observed in active cigarette smokers (10–50
ng/ml) [14]. Of note, these observed concentrations were
not corrected for the considerable baseline nicotine levels
of the subjects.
The safety of lozenges when misused was also monitored
through the assessment of the clinical status (including
cardiovascular parameters), laboratory test results and
occurrence of AEs. The different extents (according to
dose) of nicotine absorption were not reflected in BP, HR,
and ECG values, nor were any clinically significant
changes in cardiac or laboratory parameters observed. No
serious AEs were reported. Only one minor AE occurred in
groups A and B (headache during 1 h). In group C, six vol-
unteers reported transient stomach heaviness lasting for
up to 1 h after ingestion of the 12 lozenges. Gastric antral
motor activity determined at 1 and 11 h post-dosing was
identical to normal physiological values (3 ± 0.5 cycles/
min). Gastric half clearance times at 1 and 11 h post-dos-
ing were within the standard range (55 ± 15 min) for sub-
jects receiving 3 or 6 lozenges, but not for those receiving
12 lozenges; the latter complained about stomach heavi-
ness at 1 h post-dosing and displayed shortened gastric
half clearance times (26 and 34 min). However, these AEs
resolved spontaneously, and clearance half-times at 11 h
post-dosing were again well within the standard range (49
and 62 min).
Dose proportionality of nicotine lozenges with respect to  nicotine plasma concentrations (31 subjects) Figure 2
Dose proportionality of nicotine lozenges with 
respect to nicotine plasma concentrations (31 sub-
jects). Nicotine plasma concentrations were determined 
from blood samples of 31 volunteers drawn before hourly 
administration 1 or 2 mg nicotine lozenge (unconnected data 
points). Consecutive blood samples (connected data points) 
were drawn after administration of dose 12 (t = 11 h), and 
the derived data points are connected. Plasma concentra-
tions obtained with 1 mg lozenges were doubled for ease of 
comparison.
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Table 5: PK parameters of nicotine in plasma at steady state after 12 hourly doses† of 2 mg lozenge or 4 mg gum (mean ± SD; n = 31)
Formulation\PK parameter Nicotinell® lozenge Nicorette® gum 90% CI (lozenge/gum)‡
2 mg 4 mg
Cmax (ng/ml) 22.5 ± 7.0 30.5 ± 12.8 0.69–0.89 (F = 0.78)
tmax (h) Median [range] 0.5 [0.25–1.02] 0.5 [0.25–1.00] NS (Friedman ANOVA)
AUC11–12 (h·ng/ml) 20.2 ± 6.8 27.5 ± 11.4 0.68–0.88 (F = 0.77)
NS: not significant.
†: PK parameters were determined from blood samples drawn after dose 12 (t = 11 h) until t = 23 h.
‡: Standard 90% CI for the expected mean ratio (test/reference = lozenge/gum) was derived from ANOVA for continuous parameters and 
compared to standard BAR [0.80–1.25] and enlarged BAR [0.7–1.43]. F: relative bioavailability ratio.BMC Clinical Pharmacology 2007, 7:11 http://www.biomedcentral.com/1472-6904/7/11
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Efficacy of 1 mg lozenge for smoking cessation in phase 3 
trials
The two randomized placebo-controlled trials to assess
the clinical efficacy of 1 mg Nicotinell lozenge, involved
approximately 900 subjects. For both trials, the demo-
graphic characteristics of enrolled subjects, including
parameters related to past smoking history (years of
smoking, number of cigarettes per day, exhaled CO, and
urinary nicotine metabolite levels) were matched between
groups (data not shown). The only important difference
between the two studies was the level of patients' cigarette
dependence at inclusion (see Methods).
The results for the primary efficacy criterion of the French
trial on week 6 indicated a statistically significant increase
in the number of subjects continuously abstinent from
smoking with active lozenges, with an odds ratio (OR) for
abstinence of 1.72 [95% CI: 1.05–2.80] compared with
placebo (Table 7). This result was in line with previously
reported odds for quitting with NRT products in general
[9] and a polacrilex lozenge formulation 2 mg in particu-
lar [16]. The full numbers about complete abstinence
from week 2 are detailed in table 8. When the less selec-
tive, secondary efficacy criterion was applied (complete or
partial smoking abstinence on week 6), the OR for absti-
nence with the active lozenge was 2.18 [1.40–3.41], and
statistically significant differences (p < 0.05) between
active and placebo lozenges in the percentage of abstinent
smokers were found not only at week 6, but also for the
follow-up visit at week 12 (Table 7 and Figure 4). On week
26, this difference was only significant for the subgroup of
subjects previously smoking >20 cigarettes per day (data
not shown). In addition, the evolution (compared to
baseline) of the score for cessation-related withdrawal
symptoms was determined, and increases proved to be
less intense for subjects randomized to the active group (p
< 0.001) than for those in the placebo group (Figure 5).
Finally, there was no increased frequency of any side
effects in the active group and vital signs control did not
reveal any relevant differences between the two treatment
groups.
Nicotine plasma concentration after repeated intake of nicotine lozenges or gum (31 subjects) Figure 3
Nicotine plasma concentration after repeated intake of nicotine lozenges or gum (31 subjects). Nicotine plasma 
concentrations were determined from blood samples of 31 volunteers drawn before hourly administration of 1 or 2 mg nico-
tine lozenge or 4 mg nicotine gum (unconnected data points). Consecutive blood samples (connected data points) were drawn 
after administration of dose 12 (t = 11 h).
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In the US trial, analysis for the primary efficacy criterion at
week 6 also demonstrated a statistically significant superi-
ority for active vs. placebo lozenges in the number of quit-
ters who remained continuously abstinent on week 6 (OR
= 2.87 [95% CI: 1.18–6.97]) (Table 8). The proportion of
subjects continuously abstinent from week 2 through to
week 12 was also significantly higher with active lozenge
than with placebo lozenge (Table 8, Figure 6). However,
the abstinence rates were lower than in the French trial,
which might be due to patients' higher dependence levels
at inclusion. Withdrawal symptoms, assessed as total crav-
ing and total mood scores, were reduced in the active
group in comparison with the placebo group during the
steady treatment period (up to week 6), with statistically
significant differences in mean total craving scores at week
1 (p = 0.03), and weeks 2 and 3 (p < 0.01).
Overall, Nicotinell 1 mg lozenges significantly increased
the ratios of short-term abstinent from smoking patients,
with no increase in side effects compared with placebo. Of
interest, the mean consumption in the US trial, which
included more highly dependent smokers than the French
trial, consisted of 12.9 nicotine lozenges/day during the
steady treatment phase (week 1–6), and decreased from
8.8 lozenges/day (week 7) to 3.3 lozenges/day (week 12)
during the weaning phase. Corresponding amounts of
lozenges/day in the French trial were 8.7 (week 1–6), 6.2
(week 7), and 1.9 (week 12). These numbers provided evi-
dence for the self-titration behavior of smokers when
using Nicotinell® 1 mg lozenge, with subjects adjusting
their intake to their individual needs.
Discussion
This review presents PK data obtained during the clinical
development process of 1 and 2 mg Nicotinell lozenges,
which show that these formulations deliver significant
amounts of nicotine, despite lower amounts of nicotine-
base equivalents compared to the polacrilex 2 mg chewing
gum. In addition, we present clinical data, which demon-
strate that these lozenges are effective and safe for use by
smokers wanting to quit smoking.
The high addictiveness of tobacco smoking makes it diffi-
cult to quit without some form of additional help [30,31].
Pharmaceutical NRT, i.e. the administration of purified
nicotine under controlled regimens to smokers in order to
help them to stop smoking cigarettes, aims at alleviating
craving for nicotine and thereby preventing rapid relapse.
Accordingly, over the last 20 years, a body of experimental
evidence has demonstrated that the chances for motivated
smokers to successfully quit were roughly doubled when
NRT products were used [9]. Nicotine for NRT is available
Table 6: PK parameters of nicotine in plasma after swallowing without sucking of increasing numbers of 1 mg lozenge (mean ± SD; n = 
8 per group)
Group\PK parameter A B C
3 lozenges 6 lozenges 12 lozenges
Cmax (ng/ml) 8.2 ± 7.6 16.9 ± 11.8 20.5 ± 8.8
tmax (h) 2.7 ± 2.8 2.8 ± 2.0 2.2 ± 1.4
AUC10 min-12 h (h.ng/ml) 37.0 ± 27.2 84.9 ± 48.9 103.1 ± 58.6
PK parameters were not corrected for baseline plasma nicotine levels.
Table 7: Primary and secondary efficacy criteria: complete or partial abstinence during the 28 days preceding the 6-week visit 
(adopted from [17])
Group\Statistical results Nicotinell® 
lozenge 1 mg
Placebo
(n = 211) (n = 222)
Complete abstinence (%) 48 (23%) 32 (14%)
OR [95% CI] 1.72 [1.05–2.80]
Statistical significance p = 0.03
Complete or partial abstinence (%) 68 (32%) 39 (18%)
OR [95% CI] 2.18 [1.40–3.41]
Statistical significance p = 0.001
Complete abstinence = subjects declaring not to smoke + exhaled-breath CO <10 ppm. Partial abstinence = subjects smoking ≤ 1 cigarette/day and 
≤ 7 cigarettes/week + exhaled-breath CO <10 ppm.BMC Clinical Pharmacology 2007, 7:11 http://www.biomedcentral.com/1472-6904/7/11
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in a number of different pharmacological formulations,
and lozenges are among the latest additions to the arsenal
of NRT products [16,22]. Oral nicotine formulations
present both advantages and inconveniences directly
related to this route of administration: their major draw-
back, as compared with transdermal patches, is that
repeated intake of the drug is necessary to achieve sus-
tained blood nicotine levels. On the other hand, the ver-
satility of acute dosage forms allows abstinent smokers to
address temporary craving episodes, and gives them the
possibility of a behavioral response somehow similar to
the previous cigarette-linked gestures.
Oral nicotine formulations are the treatment of choice
when abstinent smokers want to keep an active control in
situations that may trigger smoking relapse, e.g. before
stressful meetings or social events [8,32]. While world-
wide the gum formulations are the most common oral
NRT products, a number of disadvantages might render
people reluctant to use them: incompatibility with dental
works or temporomandibular joint pain, cultural or social
acceptance and occurrence of AEs (e.g. hiccup or throat
irritation) [33]. In this respect, lozenges present a valuable
alternative as their use is more discrete and aesthetic.
Nicotine is best absorbed when it is in its non-ionized
form, which rapidly crosses biomembranes. Accordingly,
in the development of 1 and 2 mg Nicotinell lozenges,
particular attention has been paid to optimization of the
alkalizing resin to obtain optimal nicotine release and
absorption. The new formulations for lozenges were com-
pared to 2 and 4 mg nicotine polacrilex gum (Nicorette®),
which are pharmacologically well-characterized and were
the first oral NRT product on the market [15,26,34,35].
Comparison of PK parameters after a single dose of loz-
enge or gum showed that the amount of nicotine
absorbed through 1 mg Nicotinell lozenges is similar to
that obtained via 2 mg polacrilex gum, and that both for-
mulations have comparable kinetics. In addition, dose-
concentration proportionality between 1 and 2 mg Nico-
tinell® lozenges was evident from PK results, with a net
doubling of Cmax and AUC achieved with the 2 mg formu-
lation compared to the 1 mg formulation. The discrep-
ancy in gross nicotine delivery between Nicotinell 1 mg
lozenges and polacrilex 2 mg gum in the single-dose study
is only apparent and was not found in the latter studies,
when the sucking pattern was adapted: lozenges are
designed to be completely sucked out, whereas gum are
known to retain a significant amount of nicotine within
the resin (28% and 47% of total nicotine content, respec-
tively for 4 mg and 2 mg gum, i.e. approximately 1 mg nic-
otine for both strenght) [25]. Besides, variations among
individuals, probably due to differences in mastication
intensity, chewing techniques or oral pH could explain
some of the differences [26].
Comparable absorption of nicotine from 1 mg lozenges
and 2 mg gum was confirmed in the first multiple dose
trial, performed to compare the PK profile of both formu-
lations under conditions close to real use of NRT prod-
ucts. At steady state, all assessed PK parameters were
similar and formal bioequivalence using the standard
BAR [0.8–1.25] was demonstrated for Cmax and AUC. In
Table 8: Complete abstinence from week 2 at each visit
Time since treatment started 6 weeks 12 weeks 26 weeks
French study (FTDN 4 to7) Placebo n = 222, Nicotinell Lozenge 1 mg n = 211
Completely 
abstinent
active 48 22.7% 28 13.3% 25 11.8%
N (%) placebo 32 14.4% 20 9.0% 18 8.1%
OR [95% CI] 1.72 [1.05–2.80] 1.47 [0.82–2.65] 1.48 [0.78–2.79]
Statistical 
significance
p = 0.03 p = 0.199 p = 0.227
USA study 
(FTND ≥ 6)
Placebo n = 230, Nicotinell Lozenge 1 mg n = 230
Completely 
abstinent
active 19 8.3% 11 4.8% 8 3.5%
N (%) placebo 7 3.0% 3 1.3% 2 0.9%
OR [95% CI] 2.87 [1.18–6.97] 3.80 [1.05–13.80] 4.11 [0.83–19.55]
Statistical 
significance
p = 0.02 p = 0.03 p = 0.06
Completely abstinent = subjects declaring not to smoke + exhaled-breath CO <10 ppmBMC Clinical Pharmacology 2007, 7:11 http://www.biomedcentral.com/1472-6904/7/11
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the second multiple dose trial the dose-concentration pro-
portionality between Nicotinell® 1 and 2 mg lozenges was
confirmed, with 2 mg lozenges inducing plasma concen-
trations intermediate between those obtained with 1 mg
lozenges and 4 mg polacrilex gum.
Accordingly, the systemic exposure to nicotine with Nico-
tinell lozenges and with Nicorette gum, under conditions
reflecting the intended use, could be ranked as follows: 4
mg polacrilex gum > 2 mg Nicotinell lozenge > 1 mg Nico-
tinell lozenge = 2 mg polacrilex gum.
The criteria applied to evaluate bioequivalence between
different NRT products can give rise to discussion. Indeed,
even when the standard BAR [0.8–1.25] does not argue in
favor of bioequivalence, the enlarged BAR [0.7–1.43] is
relevant to assess bioequivalence between two oral NRT
formulations. This reasoning is based on the particular
behavior encountered in smokers: smokers regulate their
intake of nicotine by the number of cigarettes they smoke
and their inhaling mode. They achieve the desired effects
and minimize withdrawal symptoms by adjusting an indi-
vidual "optimal" blood level of nicotine [27]. Similarly,
the intake of NRT oral or nasal products is subject to self-
titration: clinical studies showed that the use of nicotine
gum or nasal spray followed a principle of self-titration
similar to that observed with cigarettes, with an ad-libi-
tum schedule resulting in more constant blood levels than
a fixed schedule [28,29]. It can reasonably be assumed
that nicotine self-titration behavior is found with all ces-
sation products administered in multiple doses per day
and favors individual adjustment of the dose to achieve
the desired effect. In this respect, bioequivalence using the
enlarged BAR [0.7–1.43] was achieved in the multiple-
dose study comparing 1 mg lozenge with 2 mg gum, even
when no adjustment for increasing nicotine release from
Smoking cessation success rates among users of 1 mg nicotine lozenges (moderately dependent patients) (adopted from [17]) Figure 4
Smoking cessation success rates among users of 1 mg nicotine lozenges (moderately dependent patients) 
(adopted from [17]). The rate of fully (no cigarettes) or partially (≤ 1 cigarette/day and ≤ 7 cigarettes/week) abstinent sub-
jects using 1 mg nicotine lozenges for abrupt quitting over the first 6 months of the French efficacy trial.
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the gum with time was applied (90% CI [lozenge/gum]
for Cmax: 0.76–0.93; for AUC11–12: 0.75–0.91).
The safety of 1 and 2 mg Nicotinell lozenges can be
assessed based on the observations of the 70 healthy adult
male smokers enrolled in the PK trials. In this study pop-
ulation exposed to single or multiple doses of lozenges,
no serious or unexpected AEs and no changes in physical
examination, vital signs, cardiovascular parameters and
laboratory values were observed. Reported AEs were mild
or (at worst) moderate in intensity, transient and com-
pletely reversible. This good tolerability of lozenges is in
line with safety results reported in previous clinical trials
with nicotine-polacrilex lozenges [16,22,36]. Even during
the complementary safety trial, with subjects swallowing
up to 12 lozenges at once, no serious or lasting AEs were
reported and the overall tolerability was rated as excellent.
Finally, the data from the two large phase 3 efficacy trials
further confirmed the safety profile of the nicotine loz-
enges, as there were no relevant differences in AE fre-
quency or nature between placebo and active groups. In
addition, the vast majority of the reported AEs could also
be attributed to the effects of abrupt smoking cessation.
The efficacy trials were designed to provide sufficient
power for the statistical analysis of the primary efficacy cri-
terion: controlled continuous smoking abstinence during
the 28 days preceding the visit scheduled at week 6. This
primary efficacy criterion was severe, as it obliged subjects
Smoking cessation success rates among users of 1 mg nicotine lozenges (highly dependent patients) Figure 6
Smoking cessation success rates among users of 1 mg nicotine lozenges (highly dependent patients). The rate of 
completely abstinent subjects using 1 mg nicotine lozenges for abrupt quitting over the first 6 months of the U.S. efficacy trial.
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Withdrawal symptom score (change vs. baseline) among  users of 1 mg nicotine lozenges (adopted from [18]) Figure 5
Withdrawal symptom score (change vs. baseline) among 
users of 1 mg nicotine lozenges (adopted from [18]).
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to stop smoking completely before the end of the second
week of treatment, compared with 3-week to 12-month
reported for some nicotine gum trials [9]. However, the
short treatment period seems to be more in line with "real
world" use by consumers [37]. In addition, the weaning
phase of 6 weeks (from week 7 to 12, after which no more
lozenges were supplied) was also relatively short com-
pared with some published nicotine gum trials, and sub-
jects starting to smoke again were excluded from follow-
up, regardless of their ensuing performance. These partic-
ularities must be remembered when interpreting the effi-
cacy results. Further, in both trials, no specific behavioral
counseling or support was provided to the studied popu-
lations. Notwithstanding these facts, the statistically sig-
nificant differences in short-term abstinence rates as well
as the odds for successful quitting with lozenge vs. pla-
cebo did underscore the efficacy of 1 mg nicotine lozenge
as a smoking cessation aid.
Comparative analysis of PK results of the 1 and 2 mg loz-
enge showed that at steady state Cmax was approximately
11 and 23 ng/ml, respectively. Notably, these levels are on
the lower end of the range of blood nicotine levels (10–50
ng/ml) observed in smokers at steady state. As nicotine
underdosing during smoking cessation is generally con-
sidered to increase the risk for failure in nicotine depend-
ent patients [13,37], the 2 mg Nicotinell lozenge may
provide increased efficacy for heavily to very heavily
dependent smokers, whereas the 1 mg dose may fulfill the
needs of light to moderate dependent smokers. Consider-
ing a possible abuse potential of the lozenges, which is
inherent to all NRT products administered in multiple
doses per day, it should be noted that in the French effi-
cacy trial urinary cotinine levels decreased not only in the
population of abstinent subjects receiving placebo, but
also in the population receiving 1 mg lozenges, thus
clearly indicating that at least short-medium term quitters
do not overdose the product.
Conclusion
The data presented in this review demonstrate high nico-
tine bioavailability, excellent safety profile and proven
short-term efficacy of Nicotinell lozenges. At nominal
equivalent doses 1 and 2 mg Nicotinell lozenges were
shown to deliver larger amounts of bioavailable nicotine
compared to the nicotine-polacrilex gum. Thus, Nicotinell
1 mg lozenge was bioequivalent to 2 mg polacrilex gum
following single as well as multiple doses, whereas the 2
mg lozenge provided nicotine levels between those of the
2 and the 4 mg polacrilex gum. Accordingly, the systemic
exposure to nicotine could be ranked: 4 mg polacrilex
gum > 2 mg Nicotinell lozenge > 1 mg Nicotinell lozenge
= 2 mg polacrilex gum
All AEs observed during the clinical development were
mild or moderate in severity, transient and completely
reversible. With respect to efficacy in smoking cessation,
significantly higher short-term abstinence rates (continu-
ous abstinence from week 2, assessed on week 6) were
achieved with lozenge compared to placebo. In conclu-
sion, Nicotinell lozenges offer a valuable addition to the
therapeutic armamentarium available for smoking cessa-
tion.
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